Keyphrases
Tertiary Care Hospital
100%
Infliximab
100%
Pediatric Inflammatory Bowel Disease
100%
Center Experience
100%
Ulcerative Colitis
27%
Crohn's Disease
27%
Adverse Events
18%
Durable Remission
18%
Loss of Response
18%
Oral Methotrexate
18%
High Dose
9%
Dose Adjustment
9%
Pediatric Patients
9%
Retrospective Cohort Study
9%
Colectomy
9%
Inflammatory Bowel Disease
9%
Medical Records
9%
Crohn's Colitis
9%
Single Center
9%
Survival Analysis
9%
Long-term Safety
9%
Treatment Failure
9%
Recurrent Infection
9%
Sufficient Follow-up
9%
Lymphoproliferative Disorders
9%
Association Analysis
9%
Sustained Remission
9%
Infusion Reaction
9%
Long-term Durability
9%
Long-term Maintenance Therapy
9%
Infliximab Failure
9%
Dose Intensification
9%
Low-dose Methotrexate
9%
Anti-infliximab Antibodies
9%
Medicine and Dentistry
Tertiary Care
100%
Pediatrics
100%
Inflammatory Bowel Disease
100%
Infliximab
100%
Ulcerative Colitis
23%
Crohn's Disease
23%
Methotrexate
23%
Low Drug Dose
15%
Adverse Event
15%
Drug Megadose
7%
Pediatrics Patient
7%
Retrospective Cohort Study
7%
Colectomy
7%
Infusion
7%
Patient with Inflammatory Bowel Disease
7%
Medical Record
7%
Survival Analysis
7%
Maintenance Therapy
7%
Patient with Crohn's Disease
7%
Recurrent Infection
7%
Lymphoproliferative Disease
7%
Patient with Ulcerative Colitis
7%
Drug Dose Intensification
7%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Infliximab
100%
Ulcerative Colitis
30%
Crohn's Disease
30%
Remission
23%
Methotrexate
23%
Adverse Event
15%
Cohort Study
7%
Recurrent Infection
7%
Lymphoproliferative Disease
7%